"DNA Mismatch Repair" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A DNA repair pathway involved in correction of errors introduced during DNA replication when an incorrect base, which cannot form hydrogen bonds with the corresponding base in the parent strand, is incorporated into the daughter strand. Excinucleases recognize the BASE PAIR MISMATCH and cause a segment of polynucleotide chain to be excised from the daughter strand, thereby removing the mismatched base. (from Oxford Dictionary of Biochemistry and Molecular Biology, 2001)
Descriptor ID |
D053843
|
MeSH Number(s) |
G02.111.222.220 G05.219.220
|
Concept/Terms |
DNA Mismatch Repair- DNA Mismatch Repair
- Mismatch Repair, DNA
- Repair, DNA Mismatch
- Mismatch Repair
- Repair, Mismatch
|
Below are MeSH descriptors whose meaning is more general than "DNA Mismatch Repair".
Below are MeSH descriptors whose meaning is more specific than "DNA Mismatch Repair".
This graph shows the total number of publications written about "DNA Mismatch Repair" by people in this website by year, and whether "DNA Mismatch Repair" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2007 | 2 | 1 | 3 |
2008 | 1 | 1 | 2 |
2009 | 5 | 6 | 11 |
2010 | 2 | 5 | 7 |
2011 | 5 | 2 | 7 |
2012 | 3 | 3 | 6 |
2013 | 7 | 2 | 9 |
2014 | 1 | 2 | 3 |
2015 | 2 | 0 | 2 |
2016 | 4 | 4 | 8 |
2017 | 8 | 1 | 9 |
2018 | 1 | 8 | 9 |
2019 | 8 | 4 | 12 |
2020 | 4 | 3 | 7 |
2021 | 4 | 3 | 7 |
2022 | 4 | 11 | 15 |
2023 | 1 | 10 | 11 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "DNA Mismatch Repair" by people in Profiles.
-
The effects of oxaliplatin-based?adjuvant?chemotherapy?in?high-risk?stage?II?colon?cancer with mismatch repair-deficient: a retrospective study. BMC Cancer. 2024 Feb 02; 24(1):164.
-
Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers. Eur J Cancer. 2024 Feb; 198:113495.
-
Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab. Gynecol Oncol. 2024 Jan; 180:139-145.
-
Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer. Eur J Cancer. 2023 11; 194:113356.
-
BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors. Oncologist. 2023 09 07; 28(9):771-779.
-
Context-dependent environmental associations with endometrial cancer histotype and genotype. Int J Gynecol Cancer. 2023 08 07; 33(8):1215-1221.
-
BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors. J Immunother Cancer. 2023 04; 11(4).
-
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023 06 08; 388(23):2145-2158.
-
Harnessing the therapeutic vulnerability of MMR heterogeneity in colorectal cancer. Cell Rep Med. 2023 01 17; 4(1):100908.
-
Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol. 2023 04 20; 41(12):2181-2190.